Addressing the issue of assessing the QoL of SMA patients in the context of comorbidities appears to be a modern approach that considers the multi-organ significance of SMN protein deficiency. This evidence concerns the gene SMN2 and hereditary thrombophilia due to congenital protein S deficiency.